Skip main navigation

Military Health System

Clear Your Cache

Health.mil has undergone a recent update. For the best user experience we recommend clearing your browser cache.

Need larger text?

USU cohort study investigates COVID-19 impacts on DOD personnel

Image of Military health personnel wearing a mask and a face shield holding up a sign that has the number eighteen on it . Navy Hospital Corpsman 3rd Class Charles Cambern holds up a numbered sign as patients circle through to receive the COVID-19 vaccine at Walter Reed National Military Medical Center, in Bethesda, Maryland. WRNMMC is one of 10 DOD sites undertaking the EPICC study to better understand COVID-19 disease. (U.S. Navy photo by Ricardo Reyes)

2/18/2021 By: HealthdotMil Staff

Share this page

Social Media Links

The Uniformed Services University of the Health Sciences’ Infectious Disease Clinical Research Program is leading a multi-year study to identify risk factors for COVID-19 in the military population, understand the symptoms and disease course, and investigate clinical outcomes.

Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential – or EPICC – study hopes to inform the Military Health System on ways to improve the patient care and treatment, infection, and disease prevention of those with COVID-19. USU is working in partnership with a network of military commands, treatment facilities, and laboratories across the country for EPICC.

Findings from the study “will support further understanding of the impact of SARS-COV-2 infection on active-duty readiness, acute and chronic clinical outcomes, the effectiveness of new treatments and vaccines, and address questions related to the emergence of new variants and their clinical impact,” said Dr. Brian Agan, deputy science director of IDCRP and principal investigator of the study.

The study is also evaluating how long the immune response to the COVID-19 vaccines lasts, breakthrough infections – which happen when a vaccinated individual becomes sick from the same illness the vaccination is designed to prevent – and how they behave over time, and estimating vaccine effectiveness, said Agan, who is also an employee of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

Department of Defense service members and MHS beneficiaries of any age with COVID-19-like illness who are admitted to the hospital or treated as outpatients at an EPICC site can join. Likewise, those 18 years or older who have been tested for COVID-19, whether they tested positive or negative, can participate in the online portion of the study, which includes self-collected blood specimens for selected participants.

The protocol was recently updated to also enroll COVID-19 vaccine recipients and will initiate recruitment upon approval, said Navy Capt. (Dr.) Timothy Burgess, program director of IDCRP, who oversees the study. Eligible beneficiaries who are interested in participating in EPICC can submit an online screening form to join.

“In addition, asymptomatic individuals with a high risk of exposure are also eligible for enrollment in EPICC, which includes health care workers and close contacts of cases,” said Burgess. “Particularly, health care workers who have received a COVID-19 vaccination will be an important population for studies to examine vaccine effectiveness and outcomes.”

Data from inpatient, outpatient, and online participants, including their clinical characteristics, comorbidities, the clinical course of their illness, treatment, immunology, and outcomes, is being collected for the study.

“Questionnaires are provided to enrollees to collect information on demographics, symptoms at initial presentation and chronic or persisting symptoms during follow-up, exposure history, and lifestyle factors,” said Burgess. “Clinical and research specimens collected from enrollees are examined using molecular, serological, and other immune assays in collaboration USU and non-USU partner laboratories.”

Initiated in March 2020, EPICC is expected to continue enrolling participants at least through March 2022, or for as long as needed to fill in the knowledge gaps related to this disease, explained Agan.

“Once enrolled, participants are actively followed for one year to fully capture specimens and data including chronic outcomes and sequelae and will be followed for up to four additional years through electronic medical record review,” Agan said.

EPICC is being conducted at 10 military medical treatment facilities throughout the United States:

  • Brooke Army Medical Center in Fort Sam Houston, Texas
  • Carl R. Darnall Army Medical Center in Fort Hood, Texas
  • Fort Belvoir Community Hospital in Fort Belvoir, Virginia
  • Joint Base Lewis-McChord, Washington
  • Naval Medical Center Portsmouth in Portsmouth, Virginia
  • Naval Medical Center San Diego in San Diego, California
  • Tripler Army Medical Center in Honolulu, Hawaii
  • William Beaumont Army Medical Center in El Paso, Texas
  • Womack Army Medical Center in Fort Bragg, North Carolina
  • Walter Reed National Military Medical Center in Bethesda, Maryland
Military health personnel wearing a face mask and shield speaking to a man who is wearing a face mask
Navy Hospital Corpsman 3rd Class Michael A. Torrent conducts a pre-screening questionnaire prior to administering the COVID-19 vaccine as part of Operation Warp Speed at Walter Reed National Military Medical Center. (U.S. Navy photo by Ricardo Reyes)

By the first week of February, more than 1,600 active-duty service members and MHS beneficiaries had enrolled in EPICC, the majority of whom are being treated as outpatients, said Agan. Approximately half of the subjects with confirmed SARS-CoV-2 diagnoses included in EPICC are active-duty service members.

Some interesting observations the researchers found thus far are that the characteristics of hospitalized COVID-19 patients compared to those treated as outpatients has shown a higher proportion of comorbidities, with hypertension, diabetes, and obesity being most prevalent, said Agan. In fact, their findings have begun to identify why obesity is a risk factor for more severe disease.

They were also able to garner valuable insight into the risk of reinfection from a military health care worker enrolled in the study who was reinfected with a symptomatic case of COVID-19. 

“A median time to recovery has been identified as 14 days, with nine lost duty days among active-duty service members,” said Agan. “These findings not only support operational planning, but also provide an important baseline to evaluate the effectiveness of vaccines as uptake widens across the DOD.”

They also found that the antibody levels that cause immunity remain in individuals for more than six months post-infection and that there were no “seroreversions” after six months post-infection. Seroreversion is the loss of serologic reactivity, or the presence of a particular antigen in the blood, whether spontaneous or in response to therapy. 

“With ongoing concerns about the magnitude and duration of immunity post-infection, our findings were both surprising and a relief,” said Burgess.

The researchers hope the information on the effectiveness and safety of the vaccines will alleviate concerns and encourage individuals to be vaccinated. And as the vaccine rollout expands to more recipients, the study will benefit from recruiting participants among the growing population of vaccinated recipients.

“This will enhance our ability to evaluate vaccine effectiveness in the population and if other reports showing high levels of protection are confirmed, our work may help boost confidence among those who are less certain,” said Burgess. “We are excited about the ability of the EPICC study to answer key questions for patients, health care providers, and leadership to guide decisions as we steer through the coming months of this unprecedented and historic pandemic.

You also may be interested in...

Policy
Mar 25, 2021

Memorandum: #20-003, COVID-19 Medical Coding Policy

.PDF | 436.92 KB

Handout that accompanies the DHA Policy Memorandum about the COVID-19 Medical Coding Policy; updated to include the 2021 procedure and diagnosis codes for COVID-19, including the new vaccination and treatment codes.

  • Identification #: 20-003
  • Type: Memorandum
Recommended Content COVID-19
Policy
Dec 31, 2020

Memorandum: Supplemental Guidance for Providing DOD Coronavirus Disease 2019 Vaccines to DOD Contractor Employees and Select Foreign Nationals

.PDF | 129.54 KB

This memorandum provides supplemental guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines, in accordance with reference (a). The Defense Health Agency (DHA) is the lead coordinating DOD Component for executing this guidance, in coordination with the Military Departments and other DOD Components as appropriate.

  • Identification #: N/A
  • Type: Memorandum
Recommended Content COVID-19
Policy
Dec 7, 2020

Memorandum: Coronavirus Disease 2019 Vaccine Guidance

This memorandum provides guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines. The Defense Health Agency (DHA) is the lead coordinating DOD Component for executing this guidance, in coordination with the Military Departments and other DOD Components.

  • Identification #: N/A
  • Type: Memorandum
Recommended Content COVID-19
Policy
Sep 11, 2015

Instruction: #DODI 6490.13, Comprehensive Policy on Traumatic Brain Injury-Related Neurocognitive Assessments by the Military Services

This instruction establishes policy, assigns responsibilities, and prescribes standard elements, pursuant to section 722 of Public Law 111-383, requiring the implementation of a comprehensive neurocognitive assessment policy in the military services.

  • Identification #: DODI 6490.13
  • Type: Instruction
Recommended Content Traumatic Brain Injury Center of Excellence Public Health Health Readiness & Combat Support
Policy
Oct 31, 2014

Memorandum: Pre-Deployment, Deployment, and Post-Deployment Training, Screening, and Monitoring Guidance for Department of Defense Personnel Deployed to Ebola Outbreak Areas

.PDF | 8.96 MB

Department of Defense personnel (Service members and civilian employees)deployed to Centers for Disease Control and Prevention defined Ebola outbreak areas will complete pre and post-deployment screening and training requirements outlined in this memorandum and supplemented by United States Africa Command (USAFRICOM) guidance.

  • Identification #: N/A
  • Type: Memorandum
Recommended Content Ebola Public Health
Policy
Oct 20, 2014

Memorandum: #13-006, Addendum to Guidance on the Establishment of Department of Defense Standardization for Ordering and Procurement of Hearing Devices Prostheses 13-006

.PDF | 94.68 KB

This memorandum clarifies procedures relating to Health Affairs' "Guidance on the Establishment of Department of Defense Standardization for Ordering and Procurement of Hearing Devices/Prosthesis," dated August 15, 2013, which remains in effect.

  • Identification #: 13-006
  • Type: Memorandum
Recommended Content Public Health
Policy
Apr 28, 2014

Instruction: #DODI 1010.10, Health Promotion and Disease Prevention

This instruction reissues DOD Directive 1010.10 (Reference (a)) as a DOD instruction (DoDI) in accordance with the authority in DODD 5124.02 (Reference (b)) to establish policy and assign responsibilities for health promotion and disease prevention in accordance with References (c) through (f).

  • Identification #: DODI 1010.10
  • Type: Instruction
Recommended Content Public Health
Skip subpage navigation
Refine your search
Last Updated: February 25, 2025
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on X Follow us on YouTube Subscribe to updates from the MHS